Author/Authors :
Segar, Jennifer M. University of Arizona Cancer Center - Tucson - Arizona 85719, USA - Department of Medicine - University of Arizona -Tucson - Arizona 85721, USA , Pandey, Ritu University of Arizona Cancer Center - Tucson - Arizona 85719, USA , Farr, Kiah J. College of Medicine - University of Arizona - Tucson - Arizona 85721, USA , Nagle, Raymond University of Arizona Cancer Center - Tucson - Arizona 85719, USA , LeBeau, Lauren Department of Pathology - University of Arizona - Tucson - Arizona 85721, USA , Gonzalez, Victor J. Department of Radiation Oncology - University of Arizona - Tucson - Arizona 85721, USA , Chalasani, Pavani University of Arizona Cancer Center - Tucson - Arizona 85719, USA - Department of Medicine - University of Arizona -Tucson - Arizona 85721, USA
Abstract :
Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular
carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher
proliferation rate and markers of cell cycle activation. We identified PILC and ILC tumors and tested for PI3K/Akt/mTOR
pathway activation by immunohistochemistry (PTEN and pS6K1) and gene expression analysis (by Nanostring nCounter
system). Proliferation index (Ki67) was elevated in 85% of PILCs compared to 20% of ILCs (p < 0:007). PTEN expression was
high in all while pS6K1 was high in 8/9 PILCs compared to 3/9 ILCs (p < 0:007). Gene expression analysis shows that PILCs
have overexpression of genes involved in cell cycle proliferation, cellular proliferation, DNA damage, and repair genes but no
difference in PI3K/Akt/mTOR pathway genes. PILCs are a biologically distinct group of ILC, and clinicopathological
characteristics suggest they would have a more clinically aggressive behavior. In addition, our results indicate that
PI3k/Akt/mTOR pathway and cell cycle proliferation are activated in majority of these tumors. Further studies are needed to
investigate these mechanisms as there are approved therapies available that may benefit PILCs.
Keywords :
Clinicopathological , Molecular Characteristics , Pleomorphic Invasive , Lobular Carcinoma